NPWT resource use compared with standard moist wound care in diabetic foot wounds: DiaFu randomized clinical trial results.


Journal

Journal of foot and ankle research
ISSN: 1757-1146
Titre abrégé: J Foot Ankle Res
Pays: England
ID NLM: 101471610

Informations de publication

Date de publication:
30 Sep 2022
Historique:
received: 20 12 2021
accepted: 24 08 2022
entrez: 30 9 2022
pubmed: 1 10 2022
medline: 5 10 2022
Statut: epublish

Résumé

Diabetic foot ulcers not only have a negative impact on patient mortality, morbidity and quality of life, but also require high resource utilization to achieve complete wound healing. The aim of this evaluation was to compare resource utilization of negative pressure wound therapy (NPWT) and standard moist wound care (SMWC) for diabetic foot wounds after amputation, surgical debridement or wound cleansing. The multicenter clinical DiaFu study enrolled 368 adults with diabetic foot ulcers between December 23, 2011 and October 21, 2014. Patients were randomly assigned to NPWT and SMWC. Evaluation of direct resource use comprised inpatient and outpatient treatment time, and personnel and material for wound treatment within 16 weeks. This resource use analysis was primarily based on the per protocol population (NPWT 44; SMWC 110). Treatment duration was 16 days shorter with NPWT (mean (SD) 82.8 (31.6), SMWC 98.8 (24.6); U test, p = 0.001) with 14.9 days shorter outpatient treatment (mean (SD) NPWT 68.3 (31.1), SMWC 83.2 (29.7)). The number of dressing changes per study participant was lower with NPWT (mean (SD) 35.1 (18.6), SMWC (42.9 (21.4); U test, p = 0.067). Time per dressing change was significantly lower with SMWC (mean (SD) 19.7 (12.8), NPWT (16.5 (8.2) minutes; U test, p < < 0.0001). Time for surgical debridements per study participant was 23.3 minutes shorter with NPWT (mean (SD) 20.5 (20.5), SMWC (43.8 (46.7); U test, p = 0.395). Resource use was lower for NPWT, which may be an efficient treatment alternative to SMWC for diabetic foot wounds, to be demonstrated in subsequent cost analyses. clinicaltrials.gov NCT01480362 on November 28, 2011.

Sections du résumé

BACKGROUND BACKGROUND
Diabetic foot ulcers not only have a negative impact on patient mortality, morbidity and quality of life, but also require high resource utilization to achieve complete wound healing. The aim of this evaluation was to compare resource utilization of negative pressure wound therapy (NPWT) and standard moist wound care (SMWC) for diabetic foot wounds after amputation, surgical debridement or wound cleansing.
METHODS METHODS
The multicenter clinical DiaFu study enrolled 368 adults with diabetic foot ulcers between December 23, 2011 and October 21, 2014. Patients were randomly assigned to NPWT and SMWC. Evaluation of direct resource use comprised inpatient and outpatient treatment time, and personnel and material for wound treatment within 16 weeks. This resource use analysis was primarily based on the per protocol population (NPWT 44; SMWC 110).
RESULTS RESULTS
Treatment duration was 16 days shorter with NPWT (mean (SD) 82.8 (31.6), SMWC 98.8 (24.6); U test, p = 0.001) with 14.9 days shorter outpatient treatment (mean (SD) NPWT 68.3 (31.1), SMWC 83.2 (29.7)). The number of dressing changes per study participant was lower with NPWT (mean (SD) 35.1 (18.6), SMWC (42.9 (21.4); U test, p = 0.067). Time per dressing change was significantly lower with SMWC (mean (SD) 19.7 (12.8), NPWT (16.5 (8.2) minutes; U test, p < < 0.0001). Time for surgical debridements per study participant was 23.3 minutes shorter with NPWT (mean (SD) 20.5 (20.5), SMWC (43.8 (46.7); U test, p = 0.395).
CONCLUSIONS CONCLUSIONS
Resource use was lower for NPWT, which may be an efficient treatment alternative to SMWC for diabetic foot wounds, to be demonstrated in subsequent cost analyses.
TRIAL REGISTRATION BACKGROUND
clinicaltrials.gov NCT01480362 on November 28, 2011.

Identifiants

pubmed: 36180953
doi: 10.1186/s13047-022-00569-w
pii: 10.1186/s13047-022-00569-w
pmc: PMC9524075
doi:

Banques de données

ClinicalTrials.gov
['NCT01480362']

Types de publication

Journal Article Multicenter Study Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

72

Subventions

Organisme : Statutory Health Insurance funds Germany
ID : Not applicable
Organisme : Kinetic Concepts Incorporated (KCI) (now part of 3M)
ID : Not applicable
Organisme : Smith&Nephew (S&N)
ID : Not applicable

Investigateurs

Martin Storck (M)
Holger Lawall (H)
Gernold Wozniak (G)
Peter Mauckner (P)
Dirk Hochlenert (D)
Walter Wetzel-Roth (W)
Klemens Sondern (K)
Matthias Hahn (M)
Gerhard Rothenaicher (G)
Thomas Krönert (T)
Karl Zink (K)

Informations de copyright

© 2022. The Author(s).

Références

Br J Surg. 2008 Jun;95(6):685-92
pubmed: 18446777
J Wound Care. 2017 Mar 1;26(Sup3):S1-S154
pubmed: 28345371
Diabetes Care. 2008 Apr;31(4):631-6
pubmed: 18162494
Control Clin Trials. 1990 Apr;11(2):116-28
pubmed: 2161310
Dtsch Arztebl Int. 2013 Jan;110(3):25-31
pubmed: 23413377
Lancet. 2005 Nov 12;366(9498):1704-10
pubmed: 16291063
Am J Surg. 2008 Jun;195(6):782-8
pubmed: 18355797
Ann Plast Surg. 1997 Jun;38(6):553-62
pubmed: 9188970
Indian J Surg. 2015 Dec;77(Suppl 2):525-9
pubmed: 26730058
Ann Plast Surg. 1997 Jun;38(6):563-76; discussion 577
pubmed: 9188971
Endocrine. 2020 Apr;68(1):44-55
pubmed: 31919770
Adv Skin Wound Care. 2004 Sep;17(7):354-64
pubmed: 15343085
J Wound Care. 2016 Mar;25(3):154, 156-9
pubmed: 26947696
J Vasc Surg. 2016 Sep;64(3):648-55
pubmed: 27565588
J Wound Care. 2005 May;14(5):224-7
pubmed: 15909439
N Engl J Med. 2017 Jun 15;376(24):2367-2375
pubmed: 28614678
Syst Rev. 2020 Oct 10;9(1):238
pubmed: 33038929
J Wound Care. 2014 May;23 Suppl 5a:S1-S41
pubmed: 25192441
Int Wound J. 2011 Feb;8(1):22-32
pubmed: 20875048
BMJ Open. 2020 Mar 24;10(3):e026345
pubmed: 32209619
J Wound Care. 2008 Feb;17(2):71-8
pubmed: 18389832
Cochrane Database Syst Rev. 2015 Jun 04;(6):CD011278
pubmed: 26042534
Adv Skin Wound Care. 2009 Mar;22(3):128-32
pubmed: 19247014
Unfallchirurg. 1996 Apr;99(4):283-7
pubmed: 8658208
Trials. 2014 Aug 27;15:334
pubmed: 25158846

Auteurs

Dörthe Seidel (D)

Institut für Forschung in der Operativen Medizin (IFOM), University of Witten/Herdecke, Ostmerheimerstraße 200 Haus 38, 51109, Köln, Germany. DoertheSeidel@gmx.de.

Rolf Lefering (R)

Institut für Forschung in der Operativen Medizin (IFOM), University of Witten/Herdecke, Ostmerheimerstraße 200 Haus 38, 51109, Köln, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH